| scholarly article | Q13442814 |
| P2093 | author name string | Leoncini G | |
| Parodi A | |||
| Deferrari G | |||
| Pontremoli R | |||
| Viazzi F | |||
| Falqui V | |||
| Ratto E | |||
| Tomolillo C | |||
| Vaccaro V | |||
| Parodi D | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE> | Q28204197 | ||
| Hypertriglyceridemia, insulin resistance, and the metabolic syndrome | Q33652030 | ||
| Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group | Q36900139 | ||
| Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events | Q40861326 | ||
| Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome | Q40864746 | ||
| Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. | Q40882910 | ||
| Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study | Q43818857 | ||
| Prognostic value of the metabolic syndrome in essential hypertension | Q44897345 | ||
| Metabolic syndrome and target organ damage in untreated essential hypertensives. | Q45054463 | ||
| Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk | Q45272071 | ||
| Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study | Q46459428 | ||
| Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential Hypertension | Q52455174 | ||
| Transesophageal Echocardiography | Q58072085 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metabolic syndrome | Q657193 |
| P304 | page(s) | 454-460 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Journal of Internal Medicine | Q6295387 |
| P1476 | title | Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients | |
| P478 | volume | 257 |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q35992444 | A Family History of Diabetes Modifies the Association between Elevated Urine Albumin Concentration and Hyperglycemia in Nondiabetic Mexican Adolescents |
| Q37304801 | Abnormal cardiac structure and function in the metabolic syndrome: a population-based study |
| Q47384108 | Association of metabolic syndrome with carotid thickening and plaque in the general population: A meta-analysis. |
| Q36812792 | Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study |
| Q36734319 | Clinical and metabolic characteristics of newly diagnosed diabetes patients: experience of a university hospital in Tunis |
| Q51472027 | Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. |
| Q37012904 | Doxazosin in metabolically complicated hypertension. |
| Q40124148 | Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients |
| Q82875049 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study |
| Q43419685 | Effects of the DASH diet on blood pressure in patients with and without metabolic syndrome: results from the DASH trial. |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q34570641 | Features of left ventricular hypertrophy in patients with metabolic syndrome with or without comparable blood pressure: a meta-analysis |
| Q46906994 | Hyperglycaemia after glucose loading is a major predictor of preclinical atherosclerosis in nondiabetic subjects |
| Q37810907 | Hypertension alone or related to the metabolic syndrome in postmenopausal women |
| Q36369676 | Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician |
| Q37485596 | Increased inflammation, reduced plasma phospholipid eicosapentaenoic acid and reduced antioxidant potential of treated hypertensive patients with metabolic syndrome |
| Q36617756 | Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease |
| Q33847586 | Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome |
| Q61456536 | Metabolic syndrome and biventricular hypertrophy in essential hypertension |
| Q36868655 | Metabolic syndrome and cardiovascular disease: challenges and opportunities |
| Q37311398 | Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. |
| Q44038990 | Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: the MAGIC study |
| Q46343761 | Metabolic syndrome and multiple organ damage in essential hypertension |
| Q37176461 | Metabolic syndrome and target organ damage: role of blood pressure |
| Q34251860 | Metabolic syndrome in hypertensive patients: An unholy alliance |
| Q33921392 | Molecular determinants of the cardiometabolic phenotype |
| Q37626852 | Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications |
| Q37095128 | Prevalence of metabolic syndrome among newly diagnosed hypertensive patients in the hills of Himachal Pradesh, India |
| Q85648282 | Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey |
| Q81569165 | Relationships between metabolic syndrome and left ventricular mass in hypertensive patients: does sex matter? |
| Q40898706 | Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance |
| Q47599267 | Subclinical target organ damage in subjects with different components of metabolic syndrome |
| Q36721716 | The Impact of Metabolic Syndrome, Homocysteine, and B Vitamins on Carotid Artery Intima-Media Thickness in Hypertensive Patients |
| Q47376797 | The influence of body composition, fat distribution, and sustained weight loss on left ventricular mass and geometry in obesity. |
| Q36416116 | The metabolic syndrome and its relationship to hypertensive target organ damage |
| Q37779720 | The metabolic syndrome following kidney transplantation |
| Q36905141 | The metabolic syndrome in hypertension: diagnostic and therapeutic implications. |
| Q37412698 | Update on the metabolic syndrome: hypertension |
| Q83140470 | Updated epidemiologic study of urolithiasis in Turkey II: role of metabolic syndrome components on urolithiasis |
Search more.